IMCR News and Press, Immunocore Holdings plc From 09/13/21

PRESS RELEASE Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US 13 September 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-...

PRESS RELEASE Immunocore Announces U K’s Medicines and Health care Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Teb entafusp in Metastatic Uveal Melanoma MHRA’s acceptance ...

PRESS RELEASE Immunocore Announces that U.S. Food and Drug Administration and European Medicine s Agency a ccept Biologics License Application and Marketing Authorization Application for T e bentafusp in M eta...

PRESS RELEASE Immunocore Reports Second Quarter 202 1 Financial Results and Provides Business Update Biologics License Application (BLA) submission for tebentafusp in metastatic uveal melanoma remains on track for...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

The following slide deck was published by Immunocore Holdings plc in conjunction with this event. For further details see: Immunocore (IMCR) Investor Presentation - Slideshow

P RESS RELEASE Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (OXF...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

P RESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development o...

Immunocore Holdings (IMCR) announces the dosing of the first patient in the first-in-human clinical trial of IMC-I109V, a new class of bispecific protein immunotherapy that is being developed for the treatment of patients with chronic hepatitis B ((HBV)) infection ((CHB)).The trial ...